Lassa virus-specific nanobodies and methods of their use
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsMitchell Ho, Peter D. Kwong, Zhijian Duan, Yaping Sun, Sao-Fong Cheung, Jason J. Gorman
Life of this patent
Estimating the term…
Abstract
Single-domain monoclonal antibodies that specifically bind Lassa virus glycoprotein (GPC) are described. The single-domain antibodies (“nanobodies”) were isolated from camel (VHH) and shark variable new antigen (VNAR) phage display libraries panned against a stabilized form of the GPC trimer. The GPC-specific nanobodies, and conjugates thereof, can be used for the diagnosis and treatment of a Lassa virus infection.
Claims23
A polypeptide that specifically binds Lassa virus (LASV) glycoprotein (GPC), wherein the polypeptide comprises:
- (i) the complementarity determining region 1 (CDR1), CDR2 and CDR3 sequences of SEQ ID NO:
- 1, wherein the CDR1, CDR2 and CDR3 sequences respectively comprise:
- residues 26-33, 51-58 and 97-104 of SEQ ID NO:
- 1;
- residues 31-35, 50-66 and 97-104 of SEQ ID NO:
- 1;
- or
- residues 26-35, 47-60 and 97-105 of SEQ ID NO:
- 1;
- or
- (ii) the CDR1, hypervariable (HV) 2, HV4 and CDR3 sequences of SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5 or SEQ ID NO:
- 6, wherein the CDR1, HV2, HV4 and CDR3 sequences respectively comprise:
- residues 26-33, 45-52, 60-64 and 84-102 of SEQ ID NO:
- 2;
- residues 26-33, 45-52, 60-64 and 84-103 of SEQ ID NO:
- 3;
- residues 26-33, 45-53, 60-64 and 84-103 of SEQ ID NO:
- 4;
- residues 26-33, 45-52, 60-64 and 84-106 of SEQ ID NO:
- 5;
- or
- residues 26-33, 45-52, 60-64 and 84-106 of SEQ ID NO:
- 6.
Dependencies are inferred from the claim text.